CANSINOBIO(06185),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06185 CANSINOBIO

Closed 01-09 16:08:42

27.850

-0.100

-0.36%

High28.550	Low27.700	Vol469.85K
Open28.000	D1 Closing27.950	Amplitude3.04%
Mkt Cap6.89B	Tradable Cap3.70B	Total Shares247.45M
T/O13.21M	T/O Rate0.35%	Tradable Shares133.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"CANSINOBIO","latestPrice":27.85,"timestamp":1736410122017,"preClose":27.95,"halted":0,"volume":469850,"delay":0,"floatShares":133000000,"shares":247449899,"eps":-6.359039555496758,"marketStatus":"Closed","change":-0.1,"latestTime":"01-09 16:08:42","open":28,"high":28.55,"low":27.7,"amount":13210272,"amplitude":0.030411,"askPrice":27.95,"askSize":17400,"bidPrice":27.85,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-3.0860493028178326,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736472600000},"marketStatusCode":5,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":27.95,"dividendRate":0.032427,"openAndCloseTimeList":[[1736386200000,1736395200000],[1736398800000,1736409600000]],"volumeRatio":0.336839,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"Cansino Biologics Inc.","latestPrice":57.1,"timestamp":1736406000000,"preClose":56.79,"halted":0,"volume":1134600,"delay":0,"premium":"-53.90"}},"requestUrl":"/m/hq/s/06185","defaultTab":"news","newsList":[{"id":"2495771510","title":"CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2495771510","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495771510?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:28","pubTimestamp":1735558136,"startTime":"0","endTime":"0","summary":"CanSino Biologics  received a drug registration certificate for its ACYW135 Meningococcal Polysaccharide Conjugate Vaccine from Indonesia's drug regulator, a Monday bourse filing said.The vaccine is indicated for the prevention of epidemic cerebrospinal meningitis in infants and children aged three months to three years.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688185","BK1515","BK0239","06185","BK1191","BK1574","BK1161"],"gpt_icon":0},{"id":"2493878652","title":"CanSino Biologics Begins Trial for Tetanus, Diptheria, Acellular Pertussis Shots","url":"https://stock-news.laohu8.com/highlight/detail?id=2493878652","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493878652?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:37","pubTimestamp":1734935832,"startTime":"0","endTime":"0","summary":"CanSino Biologics  has begun its phase 2/3 clinical trial for its combined vaccine for absorbed diphtheria, tetanus, and acellular pertussis, and enrolled its first patient in its phase 2 trial.The Tdcp vaccine is indicated for adolescents and adults aged six years old and above, according to a Friday filing with the Hong Kong exchange.CanSino's vaccine will also help address a vaccination gap for booster shots for Tdcp, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1574","BK1515","BK0239","BK1191","688185","06185"],"gpt_icon":0},{"id":"2493378504","title":"CanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2493378504","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493378504?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:29","pubTimestamp":1734935377,"startTime":"0","endTime":"0","summary":"CanSino Biologics  said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine  was officially initiated in Indonesia recently, with the first trial patient case of the Phase I clinical trial being formally enrolled, according to a Friday filing with the Hong Kong bourse.The CS-2036 is a polio treatment, a non-infectious polio vaccine developed using advanced protein design and virus-like particle  technology.The pharmaceutical stocks were down by over 1% on the Hong Kong bourse and over 2% on the Shanghai Stock Exchange in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688185","BK0239","VLP","BK1574","BK1515","BK1191","06185","BK1161"],"gpt_icon":0},{"id":"2491641846","title":"CanSino Biologics' NDA for Combined Vaccine Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2491641846","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491641846?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:50","pubTimestamp":1734349821,"startTime":"0","endTime":"0","summary":"CanSino Biologics' (HKG:6185, SHA:688185) new drug application NDA for its absorbed diphtheria, tetanus, and acellular pertussis (components) combined vaccine for infants has been accepted by China's National Medical Products Administration, a Monday bourse filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1574","BK1515","BK0239","BK1191","688185","06185"],"gpt_icon":0},{"id":"1177192004","title":"Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1177192004","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177192004?lang=en_us&edition=fundamental","pubTime":"2024-11-27 15:46","pubTimestamp":1732693593,"startTime":"0","endTime":"0","summary":"Shares of CanSinoBIO jumped 5.18% in Wednesday's trading session, outperforming the broader market, following a positive regulatory update on its meningococcal vaccine candidate Menhycia.China's National Medical Products Administration has accepted the company's supplemental application to expand the approved age range for Menhycia from 3 months to 3 years old to 3 months to 6 years old. The vaccine, which is the first MCV4 vaccine product in China, is designed to protect against meningococcal d","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06185"],"gpt_icon":0},{"id":"2486987058","title":"CanSino's Supplemental Application for Meningococcal Vaccine Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2486987058","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486987058?lang=en_us&edition=fundamental","pubTime":"2024-11-27 12:01","pubTimestamp":1732680117,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted CanSino Biologics'  supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1515","06185","BK1191","BK0239","BK1574","688185"],"gpt_icon":1},{"id":"2484916028","title":"CanSino Biologics Enrolls First Patient in Phase 1 Trial for Haemophilus Influenzae Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2484916028","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484916028?lang=en_us&edition=fundamental","pubTime":"2024-11-19 18:38","pubTimestamp":1732012686,"startTime":"0","endTime":"0","summary":"CanSino Biologics  enrolled the first patient in its phase 1 clinical trial for its haemophilus influenzae type b freeze-dried conjugate vaccine.The pathogen has two strains, one of which could cause otitis media or middle ear infection and sinusitis, and another which causes infections secondary to blood infections. It is most present in acute lower respiratory tract infections in children, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688185","BK1574","BK0239","06185","BK1515","BK1161","BK1191"],"gpt_icon":0},{"id":"2482792654","title":"CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482792654","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482792654?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:31","pubTimestamp":1731364298,"startTime":"0","endTime":"0","summary":"Despite an already strong run, CanSino Biologics Inc. ( HKG:6185 ) shares have been powering on, with a gain of 37% in...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-incs-hkg6185-price-is-right-but-growth-is","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","BK1515","BK1191","06185"],"gpt_icon":0},{"id":"2480070706","title":"CanSino Biologics Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2480070706","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480070706?lang=en_us&edition=fundamental","pubTime":"2024-11-01 09:32","pubTimestamp":1730424734,"startTime":"0","endTime":"0","summary":"CanSino Biologics ( HKG:6185 ) Third Quarter 2024 Results Key Financial Results Revenue: CN¥263.6m (up 76% from 3Q...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-third-quarter-2024-earnings-beats-expectat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06185","TTM.AU","BK1161","BK1191","BK1574","BK4523","BK4099","TTM","BK7104","BK1515"],"gpt_icon":0},{"id":"2479033844","title":"CanSino Biologics Logs 3 Million Yuan of Net Attributable Profit for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2479033844","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479033844?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:31","pubTimestamp":1730201470,"startTime":"0","endTime":"0","summary":"CanSino Biologics  recorded a net profit attributable to shareholders of 3.0 million yuan for the third quarter of 2024 while the Earnings per share stood at 0.01 yuan for the reporting period, a Tuesday filing with the Hong Kong Exchange said.The vaccine company's operating revenue for the three months ended Sept. 30 was 263.6 million yuan, 76.09% higher than a year ago.The company's shares were down nearly 2% on Tuesday's close.Price : $26.20, Change: $-0.45, Percent Change: -1.69%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK4585","HKD","06185","BK1515","BK1161","BK4023","BK1191","BK4588","BK4526"],"gpt_icon":0},{"id":"2477547401","title":"Even after rising 7.4% this past week, CanSino Biologics (HKG:6185) shareholders are still down 88% over the past three years","url":"https://stock-news.laohu8.com/highlight/detail?id=2477547401","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477547401?lang=en_us&edition=fundamental","pubTime":"2024-10-24 07:10","pubTimestamp":1729725025,"startTime":"0","endTime":"0","summary":"It is a pleasure to report that the CanSino Biologics Inc. ( HKG:6185 ) is up 39% in the last quarter. But that doesn't...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/even-after-rising-74-this-past-week-cansino-biologics-hkg618","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","BK1191","BK1515","06185"],"gpt_icon":0},{"id":"2474432249","title":"CanSino Biologics to Obtain Further $17 Million Grant from Bill & Melinda Gates Foundation for Polio Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2474432249","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474432249?lang=en_us&edition=fundamental","pubTime":"2024-10-09 19:53","pubTimestamp":1728474828,"startTime":"0","endTime":"0","summary":"CanSino Biologics  will receive a further $17 million grant from Bill & Melinda Gates Foundation for the continued development of the recombinant poliomyelitis vaccine , a Wednesday bourse filing said.The Chinese biotechnology firm had initially obtained $2 million of funding from the foundation in October 2023.The further development included clinical research, process development and scale-up, and the development of CS-2036 component combined vaccine candidatesShares of the company closed over 8% lower on Wednesday.Price : $26.10, Change: $-2.3, Percent Change: -8.10%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06185","BK4526","BK1574","BK1161","BK1515","BK4023","BK4588","BK4585","BK0239","BK1191","688185"],"gpt_icon":1},{"id":"2474248135","title":"Cansino Bio Gets Approval for Polio Vaccine Trial in Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2474248135","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474248135?lang=en_us&edition=fundamental","pubTime":"2024-10-09 18:53","pubTimestamp":1728471190,"startTime":"0","endTime":"0","summary":"Cansino Biologics  has obtained approval in Indonesia for its phase I/II clinical trial of CS-2036, a recombinant poliomyelitis vaccine.CS-2036 is a polio VLP vaccine with good safety and immunogenicity profiles, according to a Wednesday filing with the Hong Kong Exchange.The clinical trials will further evaluate the safety and immunogenicity of CS-2036 in infants and toddlers at certain ages, the filing stated.Shares of the Chinese biotechnology company closed over 8% lower on Wednesday.Price : $26.10, Change: $-2.3, Percent Change: -8.10%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1574","BK1515","BK4585","BK4526","BK4588","BK1191","BK4023","06185"],"gpt_icon":1},{"id":"2474217889","title":"BRIEF-Cansino Biologics Says Recombinant Poliomyelitis Vaccine Obtains Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2474217889","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474217889?lang=en_us&edition=fundamental","pubTime":"2024-10-09 18:19","pubTimestamp":1728469152,"startTime":"0","endTime":"0","summary":"Oct 9 (Reuters) - CanSino Biologics Inc   :   * RECOMBINANT POLIOMYELITIS VACCINE OBTAINS CLINICAL TRIAL APPROVAL IN INDONESIA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06185","BK1191","BK1161","BK1515"],"gpt_icon":0},{"id":"2474953218","title":"CanSino Biologics - Recombinant Poliomyelitis Vaccine Obtains Clinical Trial Approval in Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2474953218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474953218?lang=en_us&edition=fundamental","pubTime":"2024-10-09 16:31","pubTimestamp":1728462701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241009:nFWN3LK159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1515","BK1161","06185","BK1574"],"gpt_icon":0},{"id":"2463258837","title":"CanSino Biologics H1 Gross Profit RMB 187.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2463258837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463258837?lang=en_us&edition=fundamental","pubTime":"2024-08-29 20:37","pubTimestamp":1724935025,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240829:nPLXFB06E7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","06185","BK1515","BK1191"],"gpt_icon":0},{"id":"2463617287","title":"CanSino Biologics  Says Net Loss Narrows to 225.4 Mln Yuan in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2463617287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463617287?lang=en_us&edition=fundamental","pubTime":"2024-08-29 18:10","pubTimestamp":1724926224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240829:nL4N3KG0UC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06185","BK1515","688185","BK1161","BK0239","BK1191","BK1574"],"gpt_icon":0},{"id":"2463139287","title":"BRIEF-Cansino Biologics's Net Loss Narrows In H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2463139287","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463139287?lang=en_us&edition=fundamental","pubTime":"2024-08-29 18:10","pubTimestamp":1724926224,"startTime":"0","endTime":"0","summary":"Aug 29 (Reuters) - Cansino Biologics   :   * SAYS NET LOSS NARROWS TO 225.4 MILLION YUAN ($31.77 million) IN H1    Source text  Further company coverage:   ($1 = 7.0937 Chinese yuan renminbi) (Reporting by Beijing newsroom)((Ella.Cao@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","06185","BK1191"],"gpt_icon":0},{"id":"2459914939","title":"CanSino Biologics Inc. (HKG:6185) insiders have had a fantastic week as stock increased 10%, and they haven't stopped buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2459914939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459914939?lang=en_us&edition=fundamental","pubTime":"2024-08-13 10:33","pubTimestamp":1723516407,"startTime":"0","endTime":"0","summary":"Key Insights Significant insider control over CanSino Biologics implies vested interests in company growth The top 8...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-inc-hkg6185-insiders-have-had-a-fantastic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","06185","BK1515","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":-0.1127},{"period":"1month","weight":-0.1743},{"period":"3month","weight":0.075},{"period":"6month","weight":0.4348},{"period":"1year","weight":0.3246},{"period":"ytd","weight":-0.1127}],"compareEarnings":[{"period":"1week","weight":-0.0389},{"period":"1month","weight":-0.0556},{"period":"3month","weight":-0.0928},{"period":"6month","weight":0.0539},{"period":"1year","weight":0.1908},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.038737},{"month":2,"riseRate":0.8,"avgChangeRate":0.176312},{"month":3,"riseRate":0.2,"avgChangeRate":-0.039813},{"month":4,"riseRate":0.666667,"avgChangeRate":0.073414},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.048095},{"month":6,"riseRate":0.5,"avgChangeRate":0.040455},{"month":7,"riseRate":0.5,"avgChangeRate":0.015509},{"month":8,"riseRate":0,"avgChangeRate":-0.182296},{"month":9,"riseRate":0.666667,"avgChangeRate":0.077531},{"month":10,"riseRate":0.5,"avgChangeRate":0.079945},{"month":11,"riseRate":0.666667,"avgChangeRate":0.127077},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.021788}],"exchange":"SEHK","name":"CANSINOBIO","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CANSINOBIO(06185),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CANSINOBIO(06185) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CANSINOBIO,06185,CANSINOBIO股票,CANSINOBIO股票老虎,CANSINOBIO股票老虎国际,CANSINOBIO行情,CANSINOBIO股票行情,CANSINOBIO股价,CANSINOBIO股市,CANSINOBIO股票价格,CANSINOBIO股票交易,CANSINOBIO股票购买,CANSINOBIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CANSINOBIO(06185),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CANSINOBIO(06185) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}